MI5 chief warns AI could 'change the stakes' on bioweapons
The UK's top spy says AI is making biological attacks more accessible; Johns Hopkins' Tom Inglesby explains why governments are scrambling and what safeguards could stop it.

Loading the Newsroom
Curating from trusted global sources…
207 briefings · “nc”
The UK's top spy says AI is making biological attacks more accessible; Johns Hopkins' Tom Inglesby explains why governments are scrambling and what safeguards could stop it.
Revolut, Halifax, and Emma went dark Tuesday as Google's London cloud region failed. Here's what it means for fintech's reliance on Big Tech infrastructure.
Saudi Arabia cancels Davos in the Desert, France imposes curfews, and traders dump risk assets. Here's what the chaos means for your portfolio.
A single-zone failure at Google's London data center disrupted court hearings and left millions unable to pay or move money, exposing the fragility of cloud concentration.
A final call from Beijing puts high-net-worth individuals on notice: declare offshore trust gains by October 22 or face penalties, with ripple effects for Hong Kong's wealth hub.
Google's premium ChromeOS-Android hybrid starts at $899, but the first major review says the software can't match the hardware. A risky debut against the MacBook Air and Surface Laptop.
The U2 frontman reveals the band's pricing philosophy: affordable front rows, premium prices for the wealthy, as concert costs hit record highs and regulators circle Live Nation.
A second $45B deal would bring the pair's total to $90B and escalate the AI compute race.
A new AI tool estimates biological age from a single patient selfie, giving oncologists a fast, non-invasive survival signal - and raising questions about how far facial analysis should go.
The chief international anchor who started as an assistant in 1983 is out, forcing CNN to rethink its global news identity.
A Russian military spacecraft closed from hundreds of kilometers to extreme proximity with a commercial satellite, signaling a new orbital threat to private assets.
All-cash acquisition delivers divesiran, a late-stage-ready experimental treatment, to Merck KGaA's pipeline.